Cervical Mass Management

Anatomy and Localization

Differential Diagnosis

By Etiology

Age-Based Risk Stratification

History: Key Points

• Timing and evolution: Fluctuating/long-standing mass suggests congenital or inflammatory; persistently enlarging mass over a shorter time suggests malignancy
• Associated symptoms: Dysphagia, odynophagia, hoarseness, epistaxis, otalgia, hemoptysis, nasal obstruction, hearing loss → raise suspicion for head and neck malignancy
• Constitutional symptoms: Fever, night sweats, weight loss → lymphoma
• Risk factors: Tobacco and alcohol use, HPV exposure history (multiple sexual partners), prior radiation to head and neck, immunosuppression
• Prior treatment: A mass persisting through antibiotics may indicate an underlying anatomic abnormality or malignancy
• Travel/occupational history: Asbestos exposure, endemic mycobacterial regions

Physical Examination

• Size - masses >2 cm in adults carry >80% probability of malignancy
• Site - anterior vs. posterior triangle; level I-VII
• Shape and surface
• Consistency - firm/hard suggests malignancy; fluctuant suggests cyst or abscess
• Fixation - fixed to deep structures suggests malignancy
• Pulsatility - pulsatile with bruit = vascular (carotid body tumor, pseudoaneurysm)
• Compressibility and transillumination - cystic lesions (branchial cyst, hygroma)
• Overlying skin changes - erythema (infection), tethering (malignancy)

Diagnostic Workup

Step 1 - Imaging

• Borders and consistency (cystic vs. solid)
• Location and level
• Enhancement pattern (necrotic nodes suggest metastatic SCC)
• Relationship to adjacent structures

Step 2 - Fine-Needle Aspiration (FNA)

Step 3 - Core Biopsy

Step 4 - Open Biopsy (use with caution)

Critical principle: Never perform open/excisional biopsy of a cervical mass without a plan to convert to neck dissection if frozen section confirms carcinoma. An unplanned open biopsy can upstage disease and compromise future surgical management.

Specific Entities and Their Management

Thyroglossal Duct Cyst

• Most common congenital neck mass in children; second most common cervical mass in childhood overall
• Midline, moves with tongue protrusion and swallowing
• Treatment: Sistrunk procedure - excision of the cyst, tract, and central hyoid body (to reduce recurrence)

Branchial Cleft Cyst (2nd branchial cleft)

• Fluctuant, anterior border of SCM, upper third-middle third junction
• In patients >35 years: high index of suspicion for cystic metastatic node (especially from HPV+ oropharyngeal SCC or papillary thyroid cancer) - malignancy must be excluded before excision
• Treatment: complete excision when quiescent; passes superficial to hypoglossal and glossopharyngeal nerves

Cervical Lymphadenitis

• Most common cause of neck mass in children
• Rapidly growing, tender mass in a child: first-line treatment is antibiotics (Staph/Strep coverage)
• If no response to antibiotics: consider imaging, FNA, and broader differential (atypical mycobacteria, lymphoma)

Metastatic SCC (Unknown Primary)

• Most common malignancy in the adult neck
• Workup includes PET-CT, panendoscopy with directed biopsies (base of tongue, tonsils, piriform sinus), and HPV testing
• Management: surgery (neck dissection ± primary site treatment) + radiation/chemoradiation

Lymphoma

• Most common primary malignancy in pediatric neck
• Constitutional B-symptoms (fever, night sweats, weight loss), bilateral lymphadenopathy, mediastinal involvement
• Core or excisional biopsy for diagnosis (FNA often insufficient for subtyping); do not perform neck dissection
• Management: chemotherapy ± radiation (depends on Hodgkin vs. Non-Hodgkin subtype)

Management Summary Algorithm

Neck Mass
    ↓
History + Physical Exam (age, risk factors, mass characteristics)
    ↓
Head and Neck Exam (fiberoptic laryngoscopy, palpation of all mucosa)
    ↓
CT Neck with Contrast ± Ultrasound
    ↓
FNA Biopsy (ultrasound/CT-guided if needed)
    ↓
┌─────────────────────────────────────┐
│ Diagnosis established?              │
│ YES → Directed treatment            │
│ NO  → Core biopsy (if lymphoma      │
│        suspected)                   │
│       Open biopsy (last resort;     │
│       plan for neck dissection)     │
└─────────────────────────────────────┘

Red Flags Requiring Urgent Workup

• Adult age >35 with neck mass >2 cm
• Painless, firm, fixed mass
• Associated hoarseness, dysphagia, hemoptysis
• Unilateral serous otitis media in an adult
• Weight loss, night sweats
• Rapid progressive enlargement without infection signs

• Cummings Otolaryngology Head and Neck Surgery - Key Points and Neck Mass chapter
• Current Surgical Therapy 14e - Differential Diagnosis and Diagnostic Evaluation
• Schwartz's Principles of Surgery 11e - Neck mass evaluation
• Bailey and Love's Short Practice of Surgery 28th Ed - Lump in the neck, Branchial cyst

Cervix Mass Management

Background and Pathology

• Squamous cell carcinoma: ~80% of cases; peaks at age ~45 years
• Adenocarcinoma / adenosquamous carcinoma: ~15%; incidence increasing due to limitations of Pap smear in detecting glandular precursors
• Small cell neuroendocrine carcinoma: <5%; very poor prognosis

• Robbins & Kumar Basic Pathology; Berek & Novak's Gynecology

Differential Diagnosis of a Cervical Mass

Cervical Cancer Screening

Premalignant Disease (CIN) Management

CIN Classification

• CIN 1 (LSIL): Mitoses/immature cells confined to lower third of epithelium; a manifestation of HPV infection, not a true cancer precursor
• CIN 2 (HSIL): Middle third involvement; intermediate risk
• CIN 3 (HSIL/CIS): Upper third involvement; significant malignant potential

CIN 1 Management

• Spontaneous regression rate: 60-85% within 2 years
• Adequate colposcopy: Surveillance with co-testing (cytology + hrHPV) at 12 months
  • If negative at 12 months: return to age-appropriate screening
  • If preceded by ASC-H or HSIL cytology: co-testing at 12 and 24 months or LEEP
• CIN 1 persisting ≥24 months: Patient may choose continued surveillance OR ablation/excision (only if colposcopy adequate)
• Immunosuppressed patients: Expectant management may be inappropriate; treat more aggressively

CIN 2 and CIN 3 Management

• Women ≥25 years: Require destruction or excision of the transformation zone
• CIN 2 progression rates: ~20% progress to carcinoma in situ, ~5% to invasion if untreated
• Preferred approach: Excisional procedure (LEEP or cold-knife conization) over ablation - allows pathologic assessment of margins
• Ablation (cryotherapy/laser) is contraindicated when:
  • Colposcopy is inadequate
  • CIN 2/3 is recurrent
  • Endocervical sampling is positive
• Post-treatment: co-testing at 12 and 24 months before returning to routine screening

Adenocarcinoma In Situ (AIS)

• Must be treated with an excisional procedure (not ablation)
• Hysterectomy recommended for women who have completed childbearing (high recurrence/skip lesion risk)

Treatment Modalities for CIN

• Berek & Novak's Gynecology; Sabiston Textbook of Surgery

Invasive Cervical Cancer: FIGO Staging

Imaging in Cervical Cancer

• Tumor location (exophytic vs. endocervical)
• Tumor size
• Depth of stromal invasion
• Parametrial invasion (disruption of the low-signal cervical stromal ring)
• Vaginal and lower uterine segment extension
• Pelvic lymph node involvement

Invasive Cervical Cancer Treatment by Stage

Stage IA1 (Microinvasive, <3 mm)

• Cone biopsy (LEEP or CKC) with clear margins - acceptable for fertility preservation
• Simple hysterectomy for women who have completed childbearing
• Lymph node dissection generally not required (risk of nodal metastasis <1%)

Stage IA2 (3-5 mm invasion)

• Radical hysterectomy with pelvic lymph node dissection OR
• Radical trachelectomy (fertility-sparing) with pelvic lymph node dissection
• Risk of nodal metastasis increases to >1%, justifying lymphadenectomy

Stage IB1-IB2 / IIA (Early Locally Confined)

• Radical hysterectomy (Wertheim/type III) with sentinel lymph node biopsy or pelvic ± para-aortic lymphadenectomy = surgical standard of care
• Surgery and primary radiation are equally effective; surgery preferred in younger patients (avoids radiation-induced ovarian failure and vaginal stenosis)
• Important: Open abdominal approach is the standard of care - minimally invasive radical hysterectomy carries higher recurrence risk (especially when tumor >2 cm)
• Radical trachelectomy (fertility-sparing): option for tumors ≤2 cm in young women wanting future pregnancy

Stage IB3 / IIB and Beyond (Locally Advanced)

• Concurrent chemoradiation (external beam radiation + cisplatin-based chemotherapy) is the standard of care
• Surgery alone is NOT recommended for stages IIB and above
• Brachytherapy (intracavitary) is added after external beam for radical intent

Stage III / IVA

• Concurrent chemoradiation + brachytherapy
• IVA: may require pelvic exenteration in select cases

Stage IVB / Recurrent Disease

• Systemic chemotherapy: Carboplatin/paclitaxel ± bevacizumab is first-line
• Pembrolizumab (PD-1 inhibitor): added to chemotherapy for PD-L1 positive tumors (KEYNOTE-826 regimen)
• Pelvic exenteration for central recurrence after radiation (in selected patients)

Surgical Procedures Summary

Adjuvant Therapy after Surgery

• Positive surgical margins
• Positive lymph nodes
• Parametrial involvement

• Large tumor size
• Lymphovascular space invasion
• Deep stromal invasion

Prognosis

HPV Vaccination (Primary Prevention)

• Berek & Novak's Gynecology - CIN classification, screening guidelines, CIN management
• Sabiston Textbook of Surgery - Cervical cancer treatment, surgical techniques
• Robbins & Kumar Basic Pathology - Histopathology, morphology, clinical features
• Grainger & Allison's Diagnostic Radiology - FIGO staging table, imaging modalities
• ESGO/ESHRE/ESGE Fertility-sparing treatment guidelines 2024 (PMID 39216500)

Cervical Mass Biopsy in an Older Woman

Why Older Patients Are Different

• SCJ recession into the endocervical canal - the transformation zone (TZ) is no longer visible on the ectocervix, making colposcopy unsatisfactory in most cases
• Atrophic epithelium - pale, thin, fragile; bleeds easily; mimics acetowhite change
• Vaginal stenosis - the vaginal walls are less distensible, making speculum insertion difficult and sometimes painful
• Lugol's staining unreliable - both normal atrophic epithelium and dysplasia fail to take up iodine due to low glycogen, making Schiller's test non-discriminatory
• Dense acetowhitening from atrophic change can be confused with dysplasia

Key principle: In a postmenopausal woman without HRT, colposcopy is almost always unsatisfactory (SCJ not visible) → colposcopy-directed biopsy alone is insufficient → endocervical curettage (ECC) and/or excisional procedure (cone biopsy/LEEP) are usually required.

• Pfenninger and Fowler's Procedures for Primary Care

Pre-Procedure Assessment

History

• Last Pap smear result and HPV test result
• Prior cervical procedures (LEEP, cone, cryotherapy) - prior excision further recesses the TZ
• Postmenopausal bleeding or vaginal discharge (postmenopausal bleeding = malignancy until proven otherwise; ~10% have endometrial or cervical malignancy)
• Anticoagulants (warfarin, aspirin, clopidogrel) - may need to be held
• Vaginal estrogen use (if on local estrogen, atrophy is less severe)
• Comorbidities: diabetes, immunosuppression, cardiovascular disease

Pre-Treatment with Topical Estrogen

• Restores glycogen to squamous cells, making Lugol's test more reliable
• Reduces atrophic fragility and bleeding
• May slightly evert the SCJ, improving visualization

Pre-Procedure Medications

• Ibuprofen or naproxen 500 mg orally, 1 hour before the procedure (reduces discomfort)
• Do not schedule during heavy vaginal bleeding
• Obtain informed consent - explain the procedure, risks (bleeding, infection, discomfort, rare perforation), and planned biopsy type

Equipment Required

Step-by-Step Biopsy Procedure

Step 1 - Patient Positioning and Speculum Insertion

• Position in dorsal lithotomy with adequate lighting
• In older women with vaginal atrophy/stenosis, use a smaller, narrow-blade speculum (e.g., pediatric or small Graves speculum) - a standard bivalve speculum may cause significant discomfort or trauma
• Insert gently with warm lubricant on the outer blades (not on the cervix itself, as lubricant interferes with cytology/biopsy)
• Once the cervix is visualized, adjust speculum blades to optimize exposure

Step 2 - Initial Visualization Without Staining

• Use the colposcope to inspect the cervix at low magnification first
• Note: the os in an older woman may appear stenotic, patulous (if previously parous), or obscured
• Identify the SCJ location - in postmenopausal women it is usually within or beyond the canal (type 3 TZ)
• Note any gross lesion: exophytic mass, ulceration, friability, abnormal vascularity → if gross tumor is present, a simple directed punch biopsy of the grossest area is sufficient; colposcopy is unnecessary

If obvious tumor growth is present, a cervical biopsy is usually sufficient for diagnosis. If gross disease is not present, colposcopic examination with cervical biopsies and endocervical curettage is the next step.

• Berek & Novak's Gynecology

Step 3 - Application of 3-5% Acetic Acid

• Remove excess cervical mucus with a cotton swab or ring forceps
• Apply acetic acid liberally to the entire ectocervix and lower endocervix using a cotton swab or gauze-soaked sponge
• Wait 60 seconds - acetic acid dehydrates cells; dysplastic cells with dense nuclei turn white (acetowhite epithelium, AWE)
• In atrophic older women: atrophic epithelium itself may appear acetowhite - this is a source of false positives; more densely white, raised, thickened areas with sharp borders and abnormal vessels are more suspicious
• Dense, rapidly appearing, uniform acetowhitening in the transformation zone, especially with coarse punctation or mosaicism = high-grade CIN or cancer

Step 4 - Green Filter and Vascular Assessment

• Apply the green filter to enhance blood vessel visualization (vascular patterns appear as darker lines against green background)
• Punctation (dots) and mosaicism (tile pattern) suggest dysplasia; coarse patterns indicate higher-grade lesions
• Atypical vessels (irregular, corkscrew, branching vessels that do not taper) = suspect invasive carcinoma

Step 5 - Assess Adequacy of Colposcopy

Step 6 - Optional Lugol's Solution (Schiller's Test)

• Apply Lugol's iodine to ectocervix after acetic acid has faded
• Normal estrogenized epithelium: dark brown/mahogany (iodine-positive; glycogen-rich)
• Dysplastic/CIN tissue: remains pale yellow/white (iodine-negative = Lugol's-negative = Schiller's positive)
• Atrophic postmenopausal epithelium: also fails to stain → limited utility in older women unless pre-treated with estrogen
• Can be helpful to delineate SCJ boundaries for the colposcopist

Step 7 - Directed Punch Biopsy (Ectocervical)

• Identify the most abnormal appearing area (densest acetowhitening, coarsest vessels, most raised/thickened lesion)
• Apply topical lidocaine gel to the biopsy site, or inject 1% lidocaine with epinephrine into the cervical stroma at the biopsy site (especially helpful in older women who tolerate pain less well)
• Place the jaw of the punch biopsy forceps (Kevorkian, Schubert, or Tischler) directly over the targeted acetowhite area at the SCJ margin or the most abnormal area
• Close the jaws firmly and rotate slightly to detach the specimen; avoid crushing
• Sample multiple sites if multiple abnormal areas are present - label each separately and note the clock position (e.g., "12 o'clock", "6 o'clock")
• Biopsy the most advanced area at each site - the histopathologist makes the diagnosis, not the colposcopist
• Biopsy samples should be 2-3 mm in diameter and 2-3 mm deep to include stroma
• Place immediately in formalin-labeled containers per site

Step 8 - Endocervical Curettage (ECC) - Essential in Older Women

1. Insert the Kevorkian endocervical curette (a narrow curette with a basket tip) through the cervical os into the endocervical canal
2. In older women with a stenotic os: gently dilate with cervical dilators (Hegar #3 → #4 → #5) if needed before curettage; be gentle to avoid perforation
3. Apply systematic circumferential scraping from the internal os down to the external os, using firm but controlled pressure in all four quadrants
4. Collect the curetted material and blood with the curette basket or by swabbing the canal with a cytobrush
5. Place in a separate labeled container - ECC result is interpreted separately from punch biopsy
6. A negative ECC shows orderly benign columnar epithelium; a positive result changes management toward excisional procedure

Step 9 - Hemostasis

• Monsel's solution (ferric subsulfate paste): apply with a cotton swab directly to the biopsy site; causes chemical coagulation; highly effective
• Silver nitrate sticks: gentle pressure to the biopsy site; useful for smaller bleeding points
• Direct pressure with a cotton swab for 1-2 minutes
• Rarely: if brisk bleeding occurs from a vascular lesion, a vaginal pack or electrocautery may be needed
• Avoid: blind suturing into an atrophic, friable cervix

Special Considerations in the Elderly Patient

When to Proceed Directly to Cone Biopsy / LEEP (Not Just Punch Biopsy)

• Unsatisfactory colposcopy + high-grade cytology (HSIL) → cone biopsy or LEEP
• Positive ECC (CIN 2+ in curettings) → excisional procedure
• Suspected AIS or endocervical adenocarcinoma
• Gross lesion extending into canal
• Significant discordance between cytology and biopsy (e.g., cytology = CIS, biopsy = mild dysplasia) → re-biopsy or conization
• Recurrent CIN 2/3 after prior treatment

"An unsatisfactory colposcopic examination coupled with cytologic evidence of significant dysplasia may necessitate a cervical conization for evaluation."

• Pfenninger and Fowler's Procedures for Primary Care

Post-Procedure Instructions

• Normal: dark, coffee-ground-like vaginal discharge for 24-48 hours (Monsel's solution + blood)
• Normal: mild spotting for up to 48 hours; may resume intercourse after 24-48 hours
• Seek evaluation for: passage of clots, fresh profuse bleeding, foul vaginal odor, fever, or pelvic pain

Complications

Interpretation Pitfalls in the Elderly

• A biopsy result one degree less advanced than cytology is acceptable
• If biopsy is two or more degrees less advanced than cytology → suspect sampling error → repeat colposcopy with biopsy or proceed to conization
• Never ablate (cryotherapy, laser) a cervix with discordant cytology/histology
• Never ablate if invasive cancer is suspected - freezing invasive cancer is absolutely contraindicated

• Pfenninger and Fowler's Procedures for Primary Care, 3rd Ed - Full colposcopy technique, equipment, complications, postprocedure care
• Schwartz's Principles of Surgery 11e - Colposcopy and cervical biopsy procedure
• Berek & Novak's Gynecology - CIN management, cone biopsy indications, unsatisfactory colposcopy
• Sabiston Textbook of Surgery - Cervical surgical techniques